Vonsetamig

Unknown / undisclosed

Also known as REGN5459

Weakdesign only

Evidence outlook · no controlled comparison

NCT04083534 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma

The lead study produced no formal comparison against a control: it had a single arm, or its primary endpoint did not compare the groups (for example, a safety count). This tier describes the design, not an outcome.

NCT04083534: This early-stage study gave REGN5459 to 43 people with relapsed or refractory multiple myeloma across a range of doses, with no randomisation, no masking and no comparison group. Its primary measure was dose-limiting toxicity: one such event occurred, a grade 3 drop in blood oxygen at the highest 900 mg dose, the maximum tolerated dose was not reached, and 480 mg was chosen for later study. A study of this shape shows which doses are tolerated, not whether the drug works better than an alternative.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Also in development:Systemic Lupus Erythematosus · Phase 1Lupus Nephritis · Phase 1

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (2)
Multiple Myeloma
Other / comorbidity
NCT05092347 · Regeneron Pharmaceuticals
2022-08-02 – 2027-11-22 · Chronic Kidney Disease (CKD)
What this study did
Phase 1 (1)
Systemic Lupus Erythematosus

Competitive landscape

This mechanism is crowded: 11 other tracked programmes target it, 10 of them ahead of this one.

This drug's own stage for Lupus Nephritis: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vonsetamig: this drugPhase 1—BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Belimumab (GSK1550188) (Benlysta)ApprovedMonoclonal antibodyBAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS)Reliable signalNo reviewed efficacy summary in this indication
ObinutuzumabApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Voclosporin (Lupkynis)ApprovedSmall moleculeCalcineurin, Cyclophilin A (leading to calcineurin inhibition)Reliable signal
NCT03021499: Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks): Voclosporin — Number of renal responders: 73/179 (40.8%); Number of renal non-responders: 106/179 (59.2%) vs Placebo Oral Capsule — Number of renal responders: 40/178 (22.5%); Number of renal non-responders: 138/178 (77.5%)
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
Rapcabtagene AutoleucelPhase 2UndisclosedCD19not yet gradedNo reviewed efficacy summary in this indication
SHR-2173Phase 2UndisclosedIFNAR1 / TACInot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Vonsetamig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Phase 1/2Chronic Kidney Disease (CKD)Active not recruiting
Est. primary completion 2027-11-22 · NCT05092347 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
Phase 1Systemic Lupus ErythematosusRecruiting
Est. primary completion 2029-09-10 · NCT06975787 · CT.gov ↗
What to watch

See the full readout calendar ↗